Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.00 (0.00%)
Bid:
1.70
Ask:
2.16
Spread: 0.46 (27.059%)
Market Cap: £5.96m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Director Dealing

31 Jul 2008 16:13

For Immediate Release 31 July 2008

PROTEOME SCIENCES plc

("Proteome Sciences" or the "Company")

PRESS RELEASE

DIRECTORS' SHAREHOLDINGS

Proteome Sciences announces that on 31 July 2008 it granted a conditional award of 1,882,500 Ordinary Shares of 1p each in the Company ("Ordinary Shares") to C.D.J. Pearce, Chief Executive and of 1,170,000 Ordinary Shares of 1p each to J.L. Malthouse, Finance Director, under its Long-Term Incentive Plan ("LTIP") based on a closing mid-market price on 30 July 2008 of 20p per Ordinary Share.

In accordance with the rules of the LTIP, the Ordinary Shares awarded will vest 3 years after the date of grant subject to the Company achieving a target total shareholder return (TSR) over a three-year performance period relative to the AIM Healthcare Index at the start of that period. TSR is the aggregate of share price growth and the value of dividend payments during the performance period. No shares will be released unless the Company's TSR performance exceeds that of the index, in which case 30% of the award will vest with full vesting only if the Company's TSR performance exceeds that of the Index by 10%, with a pro-rata award between 30% and 100% for each percentage point of out-performance up to 10%.

The Remuneration Committee of the Board of Directors believes that today's award under the LTIP aligns the interests of shareholders with those of the executive by making the award dependent on the success of management in delivering superior returns to shareholders.

C.D.J. Pearce currently holds 6,538,075 shares in the Company, and has a previous conditional award under the LTIP of up to 504,523 shares.

J.L. Malthouse currently holds 625,000 shares in the Company, and has a previous conditional award under the LTIP of up to 470,352 shares.

Ends

Proteome Sciences plc

Christopher Pearce James Malthouse

Chief Executive Officer Finance Director

christopher.pearce@proteomics.com james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Nominated Adviser

Landsbanki Securities (UK) Limited

Shaun Dobson / Claes SpĴng Tel: +44 (0)20 7426 9000

vendor
Date   Source Headline
28th Jun 20064:32 pmPRNRe Licence Agreement
23rd May 20063:08 pmPRNRe Licence Agreement
26th Apr 20062:52 pmPRNBlocklisting
20th Apr 20064:39 pmPRNHolding(s) in Company
20th Apr 20064:36 pmPRNHolding(s) in Company
7th Apr 20065:20 pmRNSNotifiable Interest
22nd Mar 20064:00 pmPRNNotifiable Interest
22nd Feb 20062:30 pmRNSNotifiable Interest
13th Feb 20065:21 pmRNSNotifiable Interest Corrected
13th Feb 20065:18 pmRNSNotifiable Interest
10th Feb 20064:26 pmRNSNotifiable Interest
9th Feb 20068:30 amRNSNotifiable Interest
24th Jan 20064:32 pmRNSNotifiable Interest
25th Oct 20059:51 amPRNBlocklisting
26th Sep 200510:37 amPRNNotice of Results
5th Sep 20051:55 pmPRNHolding(s) in Company
23rd Jun 200511:18 amPRNHolding(s) in Company
20th Jun 200512:39 pmPRNHolding(s) in Company
16th Jun 20053:18 pmPRNHolding(s) in Company
7th Jun 20058:43 amPRNStatement re Grant of Options
3rd Jun 20053:32 pmPRNCorrection : Final Results
3rd Jun 20057:04 amPRNFinal Results
13th May 20051:37 pmPRNHolding(s) in Company
25th Apr 20059:48 amPRNBlocklisting
11th Apr 200510:29 amPRNHolding(s) in Company
8th Apr 20059:29 amPRNHolding(s) in Company
7th Apr 20058:13 amPRNCorrection : Holding(s) in Company
7th Apr 20057:18 amPRNHolding(s) in Company
1st Apr 20053:41 pmPRNDirector Shareholding
1st Apr 20056:00 amPRNRe Contract
1st Apr 20056:00 amPRNTrading Update & Placing
16th Mar 200510:41 amPRNHolding(s) in Company
2nd Feb 20059:24 amPRNHolding(s) in Company
6th Jan 200510:59 amRNSChange of Adviser
5th Jan 20054:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.